ProKidney Corp. filings document a late clinical-stage biotechnology issuer focused on rilparencel, an autologous renal cell therapy candidate for chronic kidney disease in patients with diabetes. Recent Form 8-K reports furnish operating and financial results, Regulation FD investor presentations, clinical-study and development-plan updates, FDA-pathway disclosures, financial-position information, and material-event or material-agreement disclosures.
Proxy materials describe annual meeting proposals, board elections, auditor ratification, stockholder voting procedures, and governance matters for the public company.
ProKidney Corp. director Brian J.G. Pereira reported exchanging paired Class B common stock and ProKidney Holdings, LLC common units into Class A common stock on August 4, 2026. He converted 81,929 paired securities held directly and 675,235 held through the Brian J. G. Pereira 2012 Irrevocable Trust, receiving equal numbers of Class A shares at a stated price of $0.00 per share. The corresponding Class B and LLC common unit interests for these amounts were reduced to zero.
PROKIDNEY CORP. reported that Chief Technical Officer Kenneth Thomas Locke received an employee stock option grant covering 750,000 shares of Class A Common Stock. The options have an exercise price of $1.8900 per share and expire on July 1, 2036.
The award is compensation-related rather than an open-market purchase. According to the vesting terms, 25% of the option vests on the first anniversary of July 1, 2026, with the remaining 75% vesting in substantially equal monthly installments over the following 36 months, subject to continued employment. Following this grant, Locke holds 750,000 derivative securities directly.
PROKIDNEY CORP. Chief Legal Officer Todd C. Girolamo converted paired interests into common stock. On June 12, 2026, he converted 163,857 Class B Common Stock and an equal number of Common Units in ProKidney Holdings, LLC into 163,857 shares of Class A Common Stock at $0.00 per share.
Following the conversion, he directly holds 327,713 shares of Class A Common Stock. The paired Class B shares and Common Units were originally received in the business combination with ProKidney LP and were exchangeable on a one-for-one basis into Class A shares.
PROKIDNEY CORP. executive Kenneth Thomas Locke, the company’s Chief Technical Officer, has filed an initial Form 3 insider ownership report. This filing establishes his status as an officer subject to insider reporting rules. The data provided show no reported purchases, sales, or other equity transactions in this submission.
PROKIDNEY CORP. director Alan Lotvin received a grant of stock options as part of non-employee director compensation. The award covers 135,000 options to buy Class A Common Stock at an exercise price of $1.81 per share, all held directly.
The options vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting and expire on May 28, 2036. Following this grant, Lotvin holds 135,000 director stock options linked to the company’s Class A Common Stock.
PROKIDNEY CORP. director Jose Ignacio Jimenez Santos received a grant of 135,000 stock options under the company’s non-employee director compensation policy. The options allow him to buy Class A Common Stock at an exercise price of $1.81 per share and expire on May 28, 2036.
The options will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual general shareholder meeting. After this award, he holds 135,000 derivative securities related to Class A Common Stock directly.
PROKIDNEY CORP. director Jennifer A. Fox received a grant of stock options as part of non-employee director compensation. She was awarded 135,000 director stock options, each allowing her to buy one share of Class A Common Stock at an exercise price of $1.81.
The options vest in full on the earlier of one year from the grant date or the company’s next annual general shareholder meeting and expire on May 28, 2036. After this grant, she holds 135,000 options directly, and this is a compensation award rather than an open-market share purchase.
PROKIDNEY CORP. director William F. Doyle reported receiving a grant of stock options as part of non-employee director compensation. He was awarded 135,000 director stock options, each allowing him to buy one share of Class A Common Stock at an exercise price of $1.81 per share.
The options were granted at no upfront cost and will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting. After this grant, Doyle holds 135,000 options directly, with an expiration date in 2036.
PROKIDNEY CORP. director Uma Sinha received a grant of options to buy 135,000 shares of Class A Common Stock at an exercise price of $1.81 per share. These director options were granted under the company’s non-employee director compensation policy and will vest in full on the earlier of one year from grant or the next annual general shareholder meeting.
PROKIDNEY CORP. director and 10% owner Pablo G. Legorreta received a grant of director stock options covering 135,000 shares of Class A Common Stock. The options have an exercise price of $1.81 per share and expire on May 28, 2036. They were granted under the company’s non-employee director compensation policy and will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting.